Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
LNTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.25 - $118.21
Previous CloseN/A
Volume177.90K
Average Volume (3M)2.16M
Market Cap
$3.78B
Enterprise Value$5.68B
Total Cash (Recent Filing)$695.57M
Total Debt (Recent Filing)$615.49M
Price to Earnings (P/E)15.1
Beta0.43
Next Earnings
Oct 30, 2025EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding67,994,150
10 Day Avg. Volume2,152,374
30 Day Avg. Volume2,155,981
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue3.73
Enterprise Value/Gross Profit5.85
Enterprise Value/Ebitda12.41
Forecast
1Y Price Target
$83.00Price Target Upside46.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst reiterates the Buy rating, expressing long-term confidence in the company's potential despite current challenges.
Portfolio ExpansionThe acquisition of Life Molecular Imaging added the FDA-approved NEURACEQ to LNTH's portfolio, expanding its diagnostic and therapeutic capabilities.
Stock BuybackThe Board of Directors authorized the repurchase of up to $400M of LNTH's common stock, which can be seen as a vote of confidence in the company's future value.
Bears Say
Competitive PressuresManagement highlighted intensified competitive pressures in the market, particularly affecting Pylarify revenues.
Market Share LossManagement expects continued market share loss, coupled with net price decline, in both the third and fourth quarter.
Revenue Guidance CutThe company lowered its guidance for the fiscal year, indicating significant cuts in both revenue and EPS projections.
Lantheus News
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $47.25 and its highest was $118.21 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $3.78B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Oct 30, 2025 which is in 63 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Aug 06, 2025. The company reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.675 by -$0.105.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.3.
How many shares outstanding does Lantheus have?
Lantheus has 67,994,150 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.57 in its last earnings report, missing expectations of $1.675. Following the earnings report the stock price went down -28.583%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
Lantheus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$83.00 (46.02% Upside)
$83.00 (46.02% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 217.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $382.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.92%
12-Months-Change
Fundamentals
Return on Equity
24.71%
Trailing 12-Months
Asset Growth
9.09%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strategic moves to enhance the company's portfolio and diversify revenue streams, such as the FDA acceptance of a new PYLARIFY formulation and key acquisitions. However, it also addressed significant challenges, including a lowered financial outlook and competitive pressures affecting PYLARIFY sales. Despite strategic efforts, the lowlights weigh heavily, indicating ongoing market challenges.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$83.00
▲(46.02% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Teva Pharmaceutical
―
Ownership Overview
2.07% Insiders
40.31% Mutual Funds
4.25% Other Institutional Investors
26.13% Public Companies and Individual Investors